Adverum Biotechnologies opens new HQ in Redwood City, San Francisco

Clical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, Adverum Biotechnologies on Tuesday announced the opening of its new corporate headquarters at one of the largest biotechnology research complexes in Redwood City, the San Francisco Bay Area.

Adverum said that its new new 80,000 square foot facility will serve as the its headquarters and will include expanded laboratory space and manufacturing process capabilities to further advance Adverum’s gene therapies.

Leone Patterson, president and chief executive officer of Adverum Biotechnologies, said that, based on the promising clinical data from the company’s lead gene therapy program, ADVM-022 in wet AMD, and its plans to pursue a second indication in diabetic retinopathy, this facility provides the opportunity to support Adverum’s future growth as the company will work on strengthening its novel vector development and manufacturing process development capabilities.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.